ClinicalTrials.gg
RecruitingNCT06897943EpGArUpdated Mar 27, 2025

Epidemiology of Gonococcal Arthritis (EpGAr)

An observational study in Gonococcal (GC) Infection and Arthritis, Infectious, sponsored by University Hospital, Brest. Recruiting at 2 sites in France. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by University Hospital, Brest · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
11
Sex
All
01

Study summary

The aim of this retrospective observational study was to describe the epidemiology of Neisseria gonorrhoeae septic arthritis over the last 10 years at Brest and Rennes university hospitals. The main question is whether there are any risk factors based on the epidemiological and clinical data on these cases. The second objective is to characterize the gonococcal strains isolated in order to determine whether there is a common clone, a virulence factor or specific resistance genes.

02

Conditions studied

  • Gonococcal (GC) Infection
  • Arthritis, Infectious

Keywords

  • gonococcal arthritis
03

In context

Gonorrhea

168 studies on the registry are indexed under Gonorrhea; 32 are open to participants now.

This study's planned enrollment of 11 is below the median of 500 across 39 observational studies indexed under Gonorrhea.

Browse Gonorrhea studies →

Lead sponsor

University Hospital, Brest is the lead sponsor of 602 studies on the registry; 137 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a Neisseria gonorrhoeae-positive joint sample (from an enrichment vial or a native sample) between 06/01/2014 and 06/30/2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a Neisseria gonorrhoeae-positive joint sample (from an enrichment vial or a native sample) between 2014 and 2024.

Exclusion criteria

Exclusion Criteria:

  • Patients with Neisseria gonorrhoeae-negative joint sample (from enrichment vial or native sample).
  • Patients who have expressed opposition to inclusion in the study.
  • Patients under legal protection (guardianship, curatorship, etc.).
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
11 participants (estimated)
Patient registry
No

Groups and cohorts

  • Gonococcal arthritis

    Patients with a positive joint sample for Neisseria gonorrhoeae between 06/01/2014 and 06/30/2024 in Brittany, France.

06

What researchers measure

Primary outcomes

  1. Age

    years

    Time frame: 10 years

  2. Date of sampling

    DD/MM/YYYY

    Time frame: 10 years

  3. Type of sample

    joint fluid or joint fluid on blood culture bottle

    Time frame: 10 years

  4. Rate of white blood cells

    quantification of white blood cells /mm3

    Time frame: 10 years

  5. Sexually transmitted infection

    associated or not, if associated, name of STI and localization

    Time frame: 10 years

  6. Men who have sex with men

    yes or no

    Time frame: 10 years

  7. HIV pre-exposure prophylaxis (PreP)

    yes or no

    Time frame: 10 years

  8. Comorbidities

    any history mentioned in the medical file, such as fracture, illness, treatment, chronic alcoholism, cancer, diabetes, etc.

    Time frame: 10 years

  9. Imaging

    medical conclusion of the ultrasound or radiology performed

    Time frame: 10 years

  10. Blood cultures (peripheral blood)

    positive or negative

    Time frame: 10 years

  11. Time to diagnosis

    in days (between onset of symptoms and antibiotics)

    Time frame: 10 years

  12. Treatments implemented

    name of the probabilistic treatment (antibiotic) and after identification or antibiogram

    Time frame: 10 years

  13. Antibiotic sensitivity profile

    Susceptibility or resistance according to SIR methodology and, if achieved: minimum inhibitory concentrations of antibiotics tested on the strain in mg/L

    Time frame: 10 years

  14. Surgery

    yes or not

    Time frame: 10 years

  15. Evolution

    recovery or relapse

    Time frame: 10 years

  16. Rate of neutrophils

    proportion of neutrophils in %.

    Time frame: 10 years

  17. Rate of CRP (C-reactive protein)

    in mg/L

    Time frame: 10 years

Secondary outcomes

  1. Molecular typing: clone

    performed on strains sent to the Centre National de Référence des IST - APHP

    Time frame: 10 years

  2. Molecular typing: virulence factors

    performed on strains sent to the Centre National de Référence des IST - APHP

    Time frame: 10 years

  3. Molecular typing: resistance genes

    performed on strains sent to the Centre National de Référence des IST - APHP

    Time frame: 10 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All collected data that underlie results in a publication

Supporting information: Study protocol

Time frame: Data will be available beginning three years and ending fifteen years following the final study report completion

Access criteria: Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Apr 2025, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 27, 2025
StartActual
Dec 1, 2024
Primary completionEst.
Apr 30, 2025
CompletionEst.
Apr 30, 2025
Last update
Mar 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06897943
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Dec 1, 2024
Primary completion
Apr 30, 2025 (estimated)
Completion
Apr 30, 2025 (estimated)
Last update
Mar 27, 2025

Study contacts

Geneviève HERY-ARNAUD
Contact
genevieve.hery-arnaud@univ-brest.fr
0298145107 ext. +33
Valentin LEMOINE
Contact
valentin.lemoine@chu-brest.fr
Geneviève HERY-ARNAUD
principal investigator · CHU de Brest

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion